ethyl 4-(aminomethyl)cyclohexanecarboxylate | 19878-18-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 4-(aminomethyl)cyclohexanecarboxylate
• 英文别名: ethyl trans-4-(aminomethyl)cyclohexanecarboxylate hydrochloride；ethyl trans-4-(aminomethyl)cyclohexylcarboxylate hydrochloride；trans-4-(aminomethyl)cyclohexane ethyl carboxylate hydrochloride
• CAS: 19878-18-3
• 化学式: C₁₀H₁₉NO₂*ClH
• 分子量: 221.727
• InChiKey: ZGOGVHCRASZRFV-JUAUBFSOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.74
• 重原子数：
  14.0
• 可旋转键数：
  3.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  52.32
• 氢给体数：
  1.0
• 氢受体数：
  3.0

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  ethyl 4-(aminomethyl)cyclohexanecarboxylate 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 67.0h， 生成
  参考文献：
  名称：

  MRI CONTRAST AGENT HAVING GADOLINIUM COMPLEX

  摘要：

  本发明涉及一种磁共振成像（MRI）对比剂，包括一种钆配合物，更具体地说是DO3A-氨甲环酸或其酯化合物，其化学式如化学式1所示。根据本发明可以制备DO3A-氨甲环酸或其酯化合物，并可以使用该化合物制备钆配合物。根据本发明制备的MRI对比剂包括作为活性成分的钆配合物，其弛豫率比目前市售的对比剂更高。此外，根据本发明的MRI对比剂具有肝脏特异性和血池对比效应的双功能性。因此，由于根据本发明包括钆配合物的MRI对比剂符合MRI对比剂所需的关键特性，它可以广泛用作MRI对比剂，并可以提供比现有对比剂更强化的对比效果。

  公开号：

  US20130231475A1
• 作为产物：
  描述：

  乙醇 、 tranexamic acid 在 氯化亚砜 作用下， 反应 12.0h， 生成 ethyl 4-(aminomethyl)cyclohexanecarboxylate
  参考文献：
  名称：

  一种含有氨甲环酸片段的异噁唑啉类衍生物及其制备和应用

  摘要：

  本发明属于杀螨剂、杀虫剂领域，具体涉及一种含有氨甲环酸片段的异噁唑啉类衍生物及其制备和应用。含有氨甲环酸片段的异噁唑啉类化合物，如通式I所示，式中各取代基团定义见说明书。通式化合物I具有优异的杀螨、杀虫活性，可用于防治螨害、虫害。式中各取代基团的定义见说明书。

  公开号：

  CN114736168A

文献信息

• Synthesis of Isothiocyanates Using DMT/NMM/TsO− as a New Desulfurization Reagent
  作者：Łukasz Janczewski、Dorota Kręgiel、Beata Kolesińska

  DOI：10.3390/molecules26092740

  日期：——

  Thirty-three alkyl and aryl isothiocyanates, as well as isothiocyanate derivatives from esters of coded amino acids and from esters of unnatural amino acids (6-aminocaproic, 4-(aminomethyl)benzoic, and tranexamic acids), were synthesized with satisfactory or very good yields (25–97%). Synthesis was performed in a “one-pot”, two-step procedure, in the presence of organic base (Et3N, DBU or NMM), and

  合成了 33 种烷基和芳基异硫氰酸酯，以及来自编码氨基酸酯和非天然氨基酸酯（6-氨基己酸、4-（氨甲基）苯甲酸和氨甲环酸）的异硫氰酸酯衍生物，合成效果令人满意或非常好。产率 (25–97%)。在有机碱（Et 3 N、DBU 或 NMM）和二硫化碳存在下，通过二硫代氨基甲酸盐，用 4-(4,6-二甲氧基-1, 3,5-三嗪-2-基)-4-甲基吗啉鎓甲苯-4-磺酸盐 (DMT/NMM/TsO - ) 作为脱硫剂。对于脂肪族和芳香族异硫氰酸酯的合成，反应在微波反应器中进行，并且在水介质中也合成了选定的烷基异硫氰酸酯，收率高（72-96%）。在没有微波辐射辅助的条件下，合成了低外消旋化度（er 99 > 1）的L-和D-氨基酸甲酯的异硫氰酸酯衍生物，并通过圆二色性证实了它们的绝对构型。评估了天然和非天然氨基酸的异硫氰酸酯衍生物对大肠杆菌和金黄色葡萄球菌菌株的抗菌活性，其中最活跃的是ITC 9e。
• Gd-complexes of DTPA-bis(amide) conjugates of tranexamic acid and its esters with high relaxivity and stability for magnetic resonance imaging
  作者：Sujit Dutta、Ji-Ae Park、Jae-Chang Jung、Yongmin Chang、Tae-Jeong Kim

  DOI：10.1039/b719440d

  日期：——

  The synthesis and the characterization of a series of DTPA-bis(amide) conjugates of tranexamic acid (L1), its esters (L2–L6), and their Gd(III) complexes of the type [Gd(L)(H2O)]·nH2O (L = L1–L6) are described. Except for the case of L1, all Gd-complexes exhibit greatly enhanced R1 relaxivity. Highest R1 reaches up to 12.9 mM−1 s−1 for [Gd(L2)(H2O)]. Such high relaxivity is reflected in the intensity enhancement of the in vivoMRI study on H-ras transgenic mice bearing hepatic tumor when employing [Gd(L2)(H2O)] as an MRI contrast agent. Thermodynamic stability constants, conditional stability constants, and the pM values demonstrate higher stability of [Gd(L)(H2O)]·nH2O (L = L1–L6) than Omniscan® under physiological conditions. The MTT assay performed on these complexes reveals cytotoxicity as low as that for Omniscan® in the concentration range required to obtain intensity enhancement in the in vivoMRI study.

  本文介绍了一系列氨甲环酸（L1）的 DTPA 双（酰胺）共轭物、其酯类（L2-L6）以及它们的[Gd(L)(H2O)]-nH2O（L = L1-L6）型钆（III）络合物的合成和表征。除 L1 外，所有钆络合物的 R1 弛豫性都大大增强。[Gd(L2)(H2O)]的 R1 最高可达 12.9 mM-1 s-1。使用[Gd(L2)(H2O)]作为磁共振成像造影剂对携带肝肿瘤的 H-ras 转基因小鼠进行体内磁共振成像研究时，其强度增强反映了这种高弛豫性。热力学稳定常数、条件稳定常数和 pM 值表明，在生理条件下，[Gd(L)(H2O)]-nH2O（L = L1-L6）的稳定性高于 Omniscan®。对这些复合物进行的 MTT 分析表明，在体内磁共振成像研究中获得强度增强所需的浓度范围内，其细胞毒性与 Omniscan® 一样低。
• Derivatives of dihydroxybenzoic acid
  申请人：KUREHA KAGAKU KOGYO KABUSHIKI KAISHA

  公开号：EP0059108A1

  公开（公告）日：1982-09-01

  Derivatives of dihydroxybenzoic acid represented by the formula (I) wherein R represents salt or an ester thereof, are useful for treating diseases such as inflammation and thrombosis. For this purpose they can be formulated into pharmaceutical compositions with pharmaceutically acceptable carriers.

  式 (I) 所代表的二羟基苯甲酸的衍生物 其中 R 代表 盐或其酯，可用于治疗炎症和血栓等疾病。为此，可将它们与药学上可接受的载体配制成药物组合物。
• 4-(Aminomethyl)cyclohexane-1-carboxylic acid derivatives
  申请人：KUREHA KAGAKU KOGYO KABUSHIKI KAISHA

  公开号：EP0055145A1

  公开（公告）日：1982-06-30

  4-[N-(3',4'-Methylenedioxybenzylidene) amino-methyl]-cyclohexane-1-carboxylic acid, or a pharmaceutically acceptable salt or a C1-C4 alkyl ester thereof, are useful for the treatment of inflammation, thrombosis, hypertension, asthma, cancer, rheumatism or systemic lupus erythematosus. These compounds can be formulated into pharmaceutical compositions and are prepared by reacting 3,4-methylene-dioxybenzaldehyde with 4-aminomethylcyclohexane-1-carboxylic acid or a C1-C4 alkyl ester thereof, and optionally converting the resulting compound into a pharmaceutically acceptable salt.

  4-[N-(3',4'-亚甲二氧基苄基)氨基甲基]-环己烷-1-羧酸或其药学上可接受的盐或 C1-C4 烷基酯可用于治疗炎症、血栓、高血压、哮喘、癌症、风湿病或系统性红斑狼疮。这些化合物可配制成药物组合物，其制备方法是将 3,4-亚甲基二氧基苯甲醛与 4-氨基甲基环己烷-1-羧酸或其 C1-C4 烷基酯反应，并将所得化合物转化为药学上可接受的盐。
• Gd-Complexes of 1,4,7,10-Tetraazacyclododecane-<i>N</i>,<i>N′</i>,<i>N</i>′′,<i>N</i>′′′-1,4,7,10-tetraacetic Acid (DOTA) Conjugates of Tranexamates as a New Class of Blood-Pool Magnetic Resonance Imaging Contrast Agents
  作者：Sungwook Gu、Hee-Kyung Kim、Gang Ho Lee、Bong-Seok Kang、Yongmin Chang、Tae-Jeong Kim

  DOI：10.1021/jm100966t

  日期：2011.1.13

  Gd-complexes of the type [Gd(L)(H2O)] xH(2)O (5a-c), where Lis DOTA conjugates of tranexamic acid (4a) and tranexamic esters (4b,c), have been prepared as a new class of MRI blood-pool contrast agents (BPCAs) Thermodynamic stability (K-GdL) and pharmacokinetic inertness of 5 compare well with or better than those of analogous MRI contrasting agents (CAs) such as Gd-DOTA and Gd-DTPA-BMA Their R-1-relaxivities are significantly higher than those of any of the clinically used MRI CAs T-1-weighted MR images of mice administered by 5c demonstrate high blood-pool effect with simultaneous contrast enhancement in liver The structural uniqueness of 5c lies in the fact that it adopts macrocyclic DOTA instead of acyclic DTPA In addition, 5c is nonionic and makes no resort to aromatic substituent() in the chelate backbone for the blood-pool enhancement The nature of hepatobiliary uptake demonstrated by 5c may be explained in terms of lipophilicity of tranexamate in the chelate (4c) The cell cytotoxicity test shows no toxicity found with 5, suggesting their use as a practical MRI BPCAs